Advertisement
U.S. markets closed

Takeda Pharmaceutical Company Limited (4502.T)

Tokyo - Tokyo Delayed Price. Currency in JPY
4,119.00+26.00 (+0.64%)
As of 10:13AM JST. Market open.
Full screen
Previous Close4,093.00
Open4,119.00
Bid4,118.00 x 0
Ask4,119.00 x 0
Day's Range4,093.00 - 4,126.00
52 Week Range3,852.00 - 4,494.00
Volume701,600
Avg. Volume3,861,642
Market Cap6.529T
Beta (5Y Monthly)0.46
PE Ratio (TTM)22.87
EPS (TTM)180.09
Earnings DateJan 30, 2025 - Feb 03, 2025
Forward Dividend & Yield196.00 (4.74%)
Ex-Dividend DateMar 28, 2025
1y Target Est4,797.94
  • GlobeNewswire

    HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

    — Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — — Milestone payment to be made to HUTCHMED from Takeda — — Fruquintinib already launched in several regions including the United States, Europe and China — HONG KONG, SHANGHAI & FLORHAM PARK, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will receive a milestone payment following the pricing approval and launch of FRUZA

  • Pharmaceutical Technology

    Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies

    The companies have teamed up to develop Takeda’s proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platforms.